6473 related articles for article (PubMed ID: 3664532)
1. Infiltration of primary and metastatic melanomas with macrophages of the 25F9-positive phenotype.
Bröcker EB; Zwadlo G; Suter L; Brune M; Sorg C
Cancer Immunol Immunother; 1987; 25(2):81-6. PubMed ID: 3664532
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression.
Bröcker EB; Zwadlo G; Holzmann B; Macher E; Sorg C
Int J Cancer; 1988 Apr; 41(4):562-7. PubMed ID: 3128489
[TBL] [Abstract][Full Text] [Related]
3. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
4. HLA-DR and 96-K antigens and intratumoral lymphocytic infiltrate in primary cutaneous melanoma as markers of tumor progression.
Brogelli L; Moretti S; Borgognoni L; Giannotti B
Dermatologica; 1990; 180(2):69-72. PubMed ID: 2311798
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic dynamics of tumor progression in human malignant melanoma.
Bröcker EB; Suter L; Brüggen J; Ruiter DJ; Macher E; Sorg C
Int J Cancer; 1985 Jul; 36(1):29-35. PubMed ID: 3860479
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical characterisation of macrophages in human liver and gastrointestinal tract: expression of CD4, HLA-DR, OKM1, and the mature macrophage marker 25F9 in normal and diseased tissue.
Hume DA; Allan W; Hogan PG; Doe WF
J Leukoc Biol; 1987 Nov; 42(5):474-84. PubMed ID: 3500252
[TBL] [Abstract][Full Text] [Related]
7. Interferon-gamma regulates the T cell response to precursor nevi and biologically early melanoma.
Guerry D; Alexander MA; Elder DE; Herlyn MF
J Immunol; 1987 Jul; 139(1):305-12. PubMed ID: 3108402
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens.
Ruiter DJ; Bergman W; Welvaart K; Scheffer E; van Vloten WA; Russo C; Ferrone S
Cancer Res; 1984 Sep; 44(9):3930-5. PubMed ID: 6204749
[TBL] [Abstract][Full Text] [Related]
9. Macrophages in melanocytic naevi.
Bröcker EB; Reckenfeld C; Hamm H; Ruiter DJ; Sorg C
Arch Dermatol Res; 1992; 284(3):127-31. PubMed ID: 1380230
[TBL] [Abstract][Full Text] [Related]
10. The initial steps of tumor progression in melanocytic lineage: a histochemical approach.
Wollina U; Kilian U; Henkel U; Schaarschmidt H; Knopf B
Anticancer Res; 1991; 11(4):1405-14. PubMed ID: 1746897
[TBL] [Abstract][Full Text] [Related]
11. Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi.
Kornstein MJ; Brooks JS; Elder DE
Cancer Res; 1983 Jun; 43(6):2749-53. PubMed ID: 6342758
[TBL] [Abstract][Full Text] [Related]
12. Immunohistological evaluation of MHC class I and II antigen expression on nevi and melanoma: relation to biology of melanoma.
D'Alessandro G; Zardawi I; Grace J; McCarthy WH; Hersey P
Pathology; 1987 Oct; 19(4):339-46. PubMed ID: 3328139
[TBL] [Abstract][Full Text] [Related]
13. Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions.
Taramelli D; Fossati G; Mazzocchi A; Delia D; Ferrone S; Parmiani G
Cancer Res; 1986 Jan; 46(1):433-9. PubMed ID: 3079589
[TBL] [Abstract][Full Text] [Related]
14. Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma.
Hersey P; Murray E; Grace J; McCarthy WH
Pathology; 1985 Jul; 17(3):385-91. PubMed ID: 2866482
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans.
Rubin JT; Elwood LJ; Rosenberg SA; Lotze MT
Cancer Res; 1989 Dec; 49(24 Pt 1):7086-92. PubMed ID: 2582450
[TBL] [Abstract][Full Text] [Related]
16. Nerve growth and expression of receptors for nerve growth factor in tumors of melanocyte origin.
Bröcker EB; Magiera H; Herlyn M
J Invest Dermatol; 1991 May; 96(5):662-5. PubMed ID: 1850772
[TBL] [Abstract][Full Text] [Related]
17. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas.
López-Nevot MA; Garcia E; Romero C; Oliva MR; Serrano S; Garrido F
Exp Clin Immunogenet; 1988; 5(4):203-12. PubMed ID: 3078572
[TBL] [Abstract][Full Text] [Related]
19. The differential reactivity of cells of the melanocytic lineage with four monoclonal antibodies against IFN-gamma inducible molecules.
Vacca A; Frassanito A; Rimoldi D; Dammacco F; Carrel S
Anticancer Res; 1992; 12(1):1-9. PubMed ID: 1348919
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies selected to discriminate between malignant melanomas and nevocellular nevi.
Ruiter DJ; Dingjan GM; Steijlen PM; van Beveren-Hooyer M; de Graaff-Reitsma C; Bergman W; van Muijen GN; Warnaar SO
J Invest Dermatol; 1985 Jul; 85(1):4-8. PubMed ID: 3891875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
